^
    Apply
    Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451)
    Phase 1/2
    Bellicum Pharmaceuticals
    Suspended
    Last update posted :
    04/20/2023
    Initiation :
    12/07/2020
    Primary completion :
    12/31/2025
    Completion :
    01/02/2027
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Torisel (temsirolimus) • BPX-603